Bystander effects of bioreductive drugs: Potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards

Radiation Research

Volumn 167, Issue 6, 2007, Pages 625-636

  Wilson, William R ^a   Hicks, Kevin O ^a   Pullen, Susan M ^a   Ferry, Dianne M ^a   Helsby, Nuala A ^a   Patterson, Adam V ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

1 AZIRIDINO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; 5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; AMINE; BENZAMIDE DERIVATIVE; CHLORMETHINE DERIVATIVE; CYTOCHROME P450 REDUCTASE; MUSTARD GAS DERIVATIVE; NITROREDUCTASE; OXYGEN; SN 23816; SN 23862; TIRAPAZAMINE; UNCLASSIFIED DRUG; WATER; ALKYLATING AGENT; PRODRUG;

ARTICLE; BIOASSAY; BYSTANDER EFFECT; CELL CULTURE; CELL HYPOXIA; CELL LINE; CONCENTRATION (PARAMETERS); CYTOTOXICITY; DRUG POTENCY; ENZYME ACTIVITY; ESCHERICHIA COLI; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLITE; PATHOLOGY; PRIORITY JOURNAL; REDUCTION; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECT; FEASIBILITY STUDY; LUNG TUMOR; OXIDATION REDUCTION REACTION; RADIATION DOSE; RADIATION EXPOSURE; RADIATION RESPONSE; TUMOR CELL LINE;

BRASSICACEAE;

ANTINEOPLASTIC AGENTS, ALKYLATING; BYSTANDER EFFECT; CELL HYPOXIA; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEASIBILITY STUDIES; HUMANS; LUNG NEOPLASMS; NITROGEN MUSTARD COMPOUNDS; OXIDATION-REDUCTION; PRODRUGS; RADIATION DOSAGE; RADIATION TOLERANCE;

EID: 33947621321     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.1667/RR0807.1     Document Type: Article

References (54)

1. J. M. Brown and W. R. Wilson, Exploiting tumor hypoxia in cancer treatment. Nat. Rev. Cancer 4, 437-447 (2004).
2. 2 predicts survival in advanced cancer of the uterine cervix. Radiother. Oncol. 26, 45-50 (1993).
3. M. Nordsmark, M. Overgaard and J. Overgaard, Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother. Oncol. 41, 31-39 (1996).
4. A. W. Fyles, M. Milosevic, R. Wong, M. C. Kavanagh, M. Pintilie, A. Sun, W. Chapman, W. Levin, L. Manchul and R. P. Hill, Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother. Oncol. 48, 149-156 (1998).
5. E. K. Rofstad, K. Sundfor, H. Lyng and C. G. Trope, Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis. Br. J Cancer 83, 354-359 (2000).
6. A. L. Harris, Hypoxia - a key regulatory factor in tumour growth. Nat. Rev. Cancer 2, 38-47 (2002).
7. P. Subarsky and R. P. Hill, The hypoxic tumour microenvironment and metastatic progression. Clin. Exp. Metastasis 20, 237-250 (2003).
8. R. S. Bindra and P. M. Glazer, Genetic instability and the tumor microenvironment: Towards the concept of microvenivronment-induced mutagenesis. Mutat. Res. 569, 75-85 (2005).
9. J. Pouyssegur, F. Dayan and N. M. Mazure, Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441, 437-443 (2006).
10. D. Rischin, L. Peters, R. Fisher, A. Macann, J. Denham, M. Poulsen, M. Jackson, L. Kenny, M. Pennimen and B. McClure, Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: A randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J. Clin. Oncol. 23, 79-87 (2005).
11. L. H. Patterson, Bioreductively activated antitumor N-oxides: The case of AQ4N, a unique approach to hypoxia-activated cancer chemotherapy. Drug Metab. Rev. 34, 581-592 (2002).
12. M. V. Papadopoulou and W. D. Bloomer, NLCQ-1 (NSC 709257): Exploiting hypoxia with a weak DNA-intercalating bioreductive drug. Clin. Cancer Res. 9, 5714-5720 (2003).
13. H. A. Seow, P. G. Penketh, K. Shyam, S. Rockwell and A. C. Sartorelli, 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[[1-(4-nitrophenyl)ethoxy]car bonyl]hydrazine: An anticancer agent targeting hypoxic cells. Proc. Natl. Acad. Sci. USA 102, 9282-9287 (2005).
14. K. Patel, Y. Gu, K. O. Hicks, G. J. Atwell, W. A. Denny, M. B. Jameson, D. Rischin, M. D. Pegram, J. Gutheil and W. R. Wilson, Metabolism and pharmacokinetics of PR-104, a hypoxia-activated nitrogen mustard prodrug in phase I clinical trial. Eur. J. Cancer 4 (Suppl.), 84 (2006).
15. A. V. Patterson, D. M. Ferry, S. J. Edwards, R. S. Singleton, K. Patel, S. M. Pullen, S. P. Syddall, K. D. Hicks, G. J. Atwell and W. R. Wilson, Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated and crosslinking agent PR-104. Clin. Cancer Res., in press.
16. A. E. Lee and W. R. Wilson, Hypoxia-dependent retinal toxicity of bioreductive anticancer prodrugs in mice. Toxicol. Appl. Pharmacol. 163, 50-59 (2000).
17. M. J. Allalunis, J. D. Chapman and A. R. Turner, Identification of a hypoxic population of bone marrow cells. Int. J. Radiat. Oncol. Biol. Phys. 9, 227-232 (1983).
18. J. S. Harrison, P. Rameshwar, V. Chang and P. Bandari, Oxygen saturation in the bone marrow of healthy volunteers. Blood 99, 394 (2002).
19. D. J. Ceradini, A. R. Kulkarni, M. J. Callaghan, O. M. Tepper, N. Bastidas, M. E. Kleinman, J. M. Capla, R. D. Galiano, J. P. Levine and G. C. Gurtner, Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat. Med. 10, 858-864 (2004).
20. B. G. Wouters and J. M. Brown, Cells at intermediate oxygen levels can be more important than the "hypoxic fraction" in determining tumor response to fractionated radiotherapy. Radiat. Res. 147, 541-550 (1997).
21. K. O. Hicks, S. J. Ohms, P. L. van Zijl, W. A. Denny, P. J. Hunter and W. R. Wilson, An experimental and mathematical model for the extravascular transport of a DNA intercalator in tumours. Br. J. Cancer 76, 894-903 (1997).
22. V. A. McNally, A. V. Patterson, K. J. Williams, R. L. Cowen, I. J. Stratford and M. Jaffar, Antiangiogenic, bioreductive and gene therapy approaches to the treatment of hypoxic tumours. Curr. Pharm. Des. 8, 1319-1333 (2002).
23. J. H. Elwell, B. G. Siim, J. W. Evans and J. M. Brown, Adaptation of human tumor cells to tirapazamine under aerobic conditions: Implications of increased antioxidant enzyme activity to mechanism of aerobic cytotoxicity. Biochem. Pharmacol. 54, 249-257 (1997).
24. W. R. Wilson, S. M. Pullen, A. Hogg, N. A. Helsby, K. O. Hicks and W. A. Denny, Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell cultures. Cancer Res. 62, 1425-1432 (2002).
25. J. C. Mason and G. Tennant, Heterocyclic N-oxides. Part VI. Synthesis and nuclear magnetic resonance spectra of 3-aminobenzo-1,2,4-triazines and their mono- and di-N-oxides. J. Chem. Soc. B 911-916 (1970).
26. D. C. Ware, B. D. Palmer, W. R. Wilson and W. A. Denny, Hypoxia-selective antitumor agents. 7. Metal complexes of aliphatic mustards as a new class of hypoxia-selective cytotoxins. Synthesis and evaluation of cobalt(III) complexes of bidentate mustards. J. Med. Chem. 36, 1839-1846 (1993).
27. G. O. Ahn, K. J. Botting, A. V. Patterson, D. C. Ware, M. Tercel and W. R. Wilson, Radiolytic and cellular reduction of a novel hypoxia-activated cobalt(III) prodrug of a chloromethylbenzindoline DNA minor groove alkylator. Biochem. Pharmacol. 71, 1683-1694 (2006).
28. B. D. Palmer, W. R. Wilson, G. J. Atwell, D. Schultz, X. Z. Xu and W. A. Denny, Hypoxia-selective antitumor agents. 9. Structure-activity relationships for hypoxia-selective cytotoxicity among analogues of 5-[N,N-bis(2-chloroethyl) amino]-2,4-dinitrobenzamide. J. Med. Chem. 37, 2175-2184 (1994).
29. N. A. Helsby, S. J. Wheeler, F. B. Pruijn, B. D. Palmer, S. Yang, W. A. Denny and W. R. Wilson, Effect of nitroreduction on the alkylating reactivity and cytotoxicity of the 2,4-dinitrobenzamide-5-aziridine CB 1954 and the corresponding nitrogen mustard SN 23862: Distinct mechanisms of bioreductive activation. Chem. Res. Toxicol. 16, 469-478 (2003).
30. C. A. Hoy, E. P. Salazar and L. H. Thompson, Rapid detection of DNA-damaging agents using repair-deficient CHO cells. Mutat. Res. 130, 321-332 (1984).
31. A. V. Patterson, M. P. Saunders, E. C. Chinje, D. C. Talbot, A. L. Harris and I. J. Stratford, Overexpression of human NADPH: Cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069. Br. J. Cancer 76, 1338-1347 (1997).
32. C. M. Stoscheck, Quantitation of protein. Methods Enzymol. 182, 50-68 (1990).
33. P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J. T. Warren, H. Bokesch, S. Kenney and M. R. Boyd, New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82, 1107-1112 (1990).
34. W. R. Wilson, S. M. Pullen, A. Hogg, S. M. Hobbs, F. B. Pruijn and K. O. Hicks, In vitro and in vivo models for evaluation of GDEPT: Quantifying bystander killing in cell cultures and tumors. In Suicide Gene Therapy: Methods and Reviews (C. J. Springer, Ed.), pp. 403-432. Humana Press, Totowa, NJ, 2003.
35. K. O. Hicks, Y. Fleming, B. G. Siim, C. J. Koch and W. R. Wilson, Extravascular diffusion of tirapazamine - effect of metabolic consumption assessed using the multicellular layer model. Int. J. Radiat. Oncol. Biol. Phys. 42, 641-649 (1998).
36. B. D. Palmer, P. van Zijl, W. A. Denny and W. R. Wilson, Reductive chemistry of the novel hypoxia-selective cytotoxin 5-[N,N-bis(2-chloroethyl) amino]-2,4-dinitrobenzamide. J. Med. Chem. 38, 1229-1241 (1995).
37. N. A. Helsby, D. M. Ferry, A. V. Patterson, S. M. Pullen and W. R. Wilson, 2-amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT. Br. J. Cancer 90, 1084-1093 (2004).
38. K. O. Hicks, B. G. Siim, F. B. Pruijn and W. R. Wilson, Oxygen dependence of the metabolic activation and cytotoxicity of tirapazamine: Implications for extravascular transport and activity in tumors. Radiat. Res. 161, 656-666 (2004).
39. C. A. Hoy, L. H. Thompson, C. L. Mooney and E. P. Salazar, Defective DNA cross-link removal in Chinese hamster cell mutants hypersensitive to bifunctional alkylating agents. Cancer Res. 45, 1737-1743 (1985).
40. C. Mothersill and C. Seymour, Radiation-induced bystander effects: Past history and future directions. Radiat. Res. 155, 759-767 (2001).
41. E. J. Hall, The bystander effect. Health Phys. 85, 31-35 (2003).
42. C. Mothersill and C. B. Seymour, Medium from irradiated human epithelial cells but not human fibroblasts reduces the clonogenic survival of unirradiated cells. Int. J. Radiat. Biol. 71, 421-427 (1997).
43. K. Laderoute, P. Wardman and A. M. Rauth, Molecular mechanisms for the hypoxia-dependent activation of 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233). Biochem. Pharmacol. 37, 1487-1495 (1988).
44. J. Wang, K. A. Biedermann and J. M. Brown, Repair of DNA and chromosome breaks in cells exposed to SR 4233 under hypoxia or to ionizing radiation. Cancer Res. 52, 4473-4477 (1992).
45. P. Wardman, Electron transfer and oxidative stress as key factors in the design of drugs selectively active in hypoxia. Curr. Med. Chem. 8, 739-761 (2001).
46. J. S. Daniels and K. S. Gates, DNA cleavage by the antitumor agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (SR4233): Evidence for involvement of hydroxyl radical. J. Am. Chem. Soc. 118, 3380-3385 (1996).
47. R. F. Anderson, S. S. Shinde, M. P. Hay, S. A. Gamage and W. A. Denny, Activation of 3-amino-1,2,4-benzotriazine 1,4-dioxide antitumor agents to oxidizing species following their one-electron reduction. J. Am. Chem. Soc. 125, 748-756 (2003).
48. Y. Jounaidi and D. J. Waxman, Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy. Cancer Res. 60, 3761-3769 (2000).
49. R. P. Hill, S. Gulyas and G. F. Whitmore, Toxicity of RSU-1069 for KHT cells treated in vivo or in vitro: Evidence for a diffusible toxic product. Int. J. Radiat. Oncol. Biol. Phys. 16, 1111-1114 (1989).
50. J. L. Bolton and R. A. McClelland, Kinetics and mechanism of the decomposition in aqueous solutions of 2-(hydroxylamino)imidazoles. J. Am. Chem. Soc. 111, 8172-8181 (1989).
51. L. R. Berube, K. Harasiewicz, F. S. Foster, E. Dobrowsky, M. D. Sherar and A. M. Rauth, Use of a high frequency ultrasound microscope to image the action of 2-nitroimidazoles in multicellular spheroids. Br. J. Cancer 65, 633-640 (1992).
52. R. J. Knox, F. Friedlos, M. Jarman and J. J. Robert, A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydrozylamino-2- nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by nitroreductase enzyme in Walker carcinoma cells. Biochem. Pharmacol. 37, 4661-4669 (1988).
53. G. M. Anlezark, R. G. Melton, R. F. Sherwood, W. R. Wilson, W. A. Denny, B. D. Palmer, R. J. Knox, F. Friedlos and A. Williams, Bioactivation of dinitrobenzamide mustards by an E. coli B nitroreductase. Biochem. Pharmacol. 50, 609-618 (1995).
54. E. Johansson, G. Parkinson, W. A. Denny and S. Neidle, Studies on the nitroreductase prodrug-activating system. Crystal structures of complexes with the inhibitor dicoumarol and dinitrobenzamide prodrugs and of the enzyme active form. J. Med. Chem. 46, 4009-4020 (2003).